Injectable Drug Delivery Devices Market To Reach $236.5 Billion By 2033

Injectable Drug Delivery Devices Market Growth & Trends

The global injectable drug delivery devices market size is estimated to reach USD 236.5 billion by 2033, expanding at a CAGR of 9.6% from 2026 to 2033, according to a new report by Grand View Research, Inc. The increase in the number of chronic diseases like diabetes and cancer has fueled the need for injectable drug delivery. Unlike other traditional forms of drug delivery, injectables allow maximum bioavailability of the pharmaceutical drug as it bypasses the first-pass metabolism. With substantial growth in technological advancements, the devices being manufactured and marketed are built so as to cater to the specific needs of the patients.

With the advent of self-injection devices, injectable drugs can be self-administered without the need for medical assistance. A large number of technology-oriented developments have taken place in the biologics market, which further increases the applicability of these injectable devices in the challenging disease areas. Self-injection devices have allowed patients suffering from diabetes to manage insulin levels with auto-injectors, pen-injectors, and needle-free injectors; thus, the homecare segment has been a large grosser in the end-user application.

The major restraints in this market are injuries and infections caused by needles, ambiguities related to regulatory reimbursements, sterility of the injectable drugs, and the preference of other drug delivery systems that possess less toxicity and are easy to administer. Despite these restraints, the market potential for injectable drug delivery products is tremendous with the majority of the key players opting to injectables over other forms of delivery. The injectable drug delivery industry, based on product type is segmented into two sub-types namely self-injection devices and conventional injection devices. Further, on the basis of therapeutic use, the injectable drug delivery industry is segmented into autoimmune disorders, hormonal disorders, oncology, and others.

The injectable drug delivery industry by end-user application is categorized into hospitals, home care settings, and others including research establishments, diagnostics, and clinical laboratories.

 Request a free sample copy or view report summary: Injectable Drug Delivery Devices Market Report

Injectable Drug Delivery Devices Market Report Highlights

• The diabetes mellitus segment dominated the market in 2025, primarily due to the high global prevalence of diabetes and the frequent need for injectable therapies such as insulin and GLP-1 drugs.

• The hospitals segment is projected to grow at the second-fastest CAGR from 2026 to 2033. Hospitals are increasingly adopting advanced injectable devices due to their ability to provide rapid therapeutic effects, which is crucial in emergency care and critical situations.

• North America injectable drug delivery devices market dominated with 50.0% market share in 2023. North America has a significant population with chronic diseases such as diabetes, cancer, and autoimmune disorders.

Injectable Drug Delivery Devices Market Segmentation

Grand View Research has segmented the global injectable drug delivery devices market based on product, therapeutic use, end use, and region:

Injectable Drug Delivery Devices Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

• Injectors

  • GLP-1 Agonists

  • Hormone Therapies

  • Biologics

  • Others

• Pen

  • GLP-1 Agonists

  • Insulin

  • Hormone Therapies

  • Others

Injectable Drug Delivery Devices Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

• Autoimmune Disorders

• Hormonal Disorders

• Oncology

• Obesity

• Diabetes Mellitus

• Others

Injectable Drug Delivery Devices End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

• Hospitals

• Homecare Settings

• Others

Injectable Drug Delivery Devices Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Sweden

  • Denmark

• Asia

  • China

  • Japan

  • India

  • Thailand

  • South Korea

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Injectable Drug Delivery Devices Market

• Novo Nordisk A/S

• Sanofi

• Eli Lilly and Company

• AstraZeneca plc

• Pfizer, Inc.

• Merck KGaA

• Teva Pharmaceuticals

• Amgen, Inc.

• Ferring Pharmaceuticals

• AbbVie Inc.